Serum anti–vaccinia virus antibodies and anti–vaccinia virus memory B cells in splenectomized (SPL) patients
Patient . | Age at sample collection, y . | Years after splenectomy . | Anti–vaccinia virus IgG, serum dilution ratio . | % vaccinia virus–specific memory B cells in blood . |
---|---|---|---|---|
SPL1 | 60 | 50 | 1.10 | 0.010 |
SPL2 | 59 | 44 | 0.20 | 0.041 |
SPL3 | 52 | 7 | 0.34 | 0.009 |
SPL4 | 46 | 35 | 0.28 | <0.009* |
SPL5 | 35 | 30 | 0.01 | 0.062 |
Patient . | Age at sample collection, y . | Years after splenectomy . | Anti–vaccinia virus IgG, serum dilution ratio . | % vaccinia virus–specific memory B cells in blood . |
---|---|---|---|---|
SPL1 | 60 | 50 | 1.10 | 0.010 |
SPL2 | 59 | 44 | 0.20 | 0.041 |
SPL3 | 52 | 7 | 0.34 | 0.009 |
SPL4 | 46 | 35 | 0.28 | <0.009* |
SPL5 | 35 | 30 | 0.01 | 0.062 |
Maximum estimate for individuals for whom memory B cells were undetectable.